Mektovi
Named-patient access overview. Mektovi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Mektovi (binimetinib) is Pfizer's MEK inhibitor, used in combination with encorafenib (Braftovi) for BRAF V600E or V600K mutation-positive metastatic melanoma and for BRAF V600E mutation-positive metastatic non-small cell lung cancer. It received FDA approval in 2018 for melanoma and added the NSCLC indication in 2023. For Saudi Arabia patients with a confirmed BRAF V600 mutation and a treating oncologist's recommendation for the encorafenib-plus-binimetinib regimen, this page describes the SFDA Personal Importation Program pathway.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Mektovi
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Mektovi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Mektovi in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Mektovi
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.